 Lipocine Inc. NASDAQ: LPCN, a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that the U.S. Court of Appeals for the Federal Circuit affirmed the decision of the Patent Trial and Appeal Board PTAB of the United States Patent and Trademark Office USPTO under Rule 36. Previously the PTAB granted Lipocines Priority Motion in the interference case, Patent Interference No. 106,045, between Clarus Therapeutics, Inc. Clarus U.S. Patent No. 8,828,428 the Clarus 428 Patent and Lipocine Inc. Lipocine, U.S. Patent Application No. 14713,692 the Lipocine 692 Application, and entered adverse judgment against Clarus. 